Exelixis
EXEL
#1695
Rank
S$13.38 B
Marketcap
$46.86
Share price
-3.83%
Change (1 day)
50.58%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.38. In 2022 the company made an earnings per share (EPS) of $0.77 a decrease over its 2021 EPS that were of $1.00.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-50.35%
2022$0.77-22.97%
2021$1.00100%
2020$0.50-65.09%
2019$1.43-53.91%
2018$3.11333.96%
2017$0.72-260.61%
2016-$0.45-58.75%
2015-$1.08-42.45%
2014-$1.885.3%
2013-$1.7843.48%
2012-$1.24-264.29%
2011$0.76-165.88%
2010-$1.15-32.54%
2009-$1.70-17.65%
2008-$2.0775.86%
2007-$1.18-25.64%
2006-$1.588.33%
2005-$1.46-42.86%
2004-$2.5530.34%
2003-$1.96-5.23%
2002-$2.07-0.65%
2001-$2.08-51.88%
2000-$4.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.73 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.30 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.46 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.36 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.11 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.03 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.51 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.51-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.13-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA